Also trades as: LSBCF (OTC) · $vol 0M
LSB NASDAQ
LakeShore Biopharma Co., Ltd
1W: +1.3%
1M: -2.7%
3M: -25.0%
1Y: -79.4%
3Y: -99.2%
$0.63
Last traded 2025-10-16 — delisted
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$615M
+7.2% ▲
4Y CAGR: +24.4%
Gross Profit
$507M
+11.3% ▲
4Y CAGR: +26.6%
Operating Income
-$86M
+80.6% ▲
Net Income
-$100M
+76.9% ▲
EPS (Diluted)
$-0.94
+76.8% ▲
EBITDA
-$49M
+86.8% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $257M | $503M | $687M | $573M | $615M |
| YoY Growth | +0.0% | +95.7% | +36.6% | -16.6% | +7.2% |
| Cost of Revenue | $60M | $121M | $153M | $118M | $108M |
| Gross Profit | $197M | $381M | $534M | $456M | $507M |
| Gross Margin | 76.8% | 75.9% | 77.7% | 79.5% | 82.5% |
| R&D Expenses | $94M | $211M | $319M | $303M | $146M |
| SG&A Expenses | $208M | $273M | $333M | $428M | $391M |
| Operating Expenses | $323M | $500M | $673M | $902M | $593M |
| Operating Income | -$126M | -$119M | -$139M | -$446M | -$86M |
| Operating Margin | -49.0% | -23.7% | -20.3% | -77.7% | -14.0% |
| Interest Expense | $30M | $3M | $31M | $44M | $16M |
| Income Before Tax | -$191M | -$232M | -$282M | -$455M | -$101M |
| Tax Expense | $17M | $5M | $1M | -$22M | -$947K |
| Net Income | -$192M | -$237M | -$145M | -$433M | -$100M |
| Net Margin | -74.6% | -47.1% | -21.2% | -75.6% | -16.3% |
| EPS (Diluted) | $-6.67 | $-0.02 | $-1.88 | $-4.05 | $-0.94 |
| EBITDA | -$117M | -$67M | -$77M | -$369M | -$49M |
| Shares Outstanding | 29M | 30M | 77M | 107M | 107M |